Haploidentical Hematopoietic Stem Cell Transplantation for Relapsed/Refractory Extramedullary Multiple Myeloma: A Conditioning Regimen Combining Selinexor and Helical Tomotherapy—A Case Report and Literature Review

Authors: Chen B, Guo R, Niu Y, Guo W, Wang T

Source: Journal of Blood Medicine, Vol Volume 16, Pp 177-185 (2025)

Subject Terms: allogeneic hematopoietic stem cell transplantation, relapsed/refractory multiple myeloma； extramedullary multiple myeloma, selinexor, tomotherapy, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://www.dovepress.com/haploidentical-hematopoietic-stem-cell-transplantation-for-relapsedref-peer-reviewed-fulltext-article-JBM; https://doaj.org/toc/1179-2736

Access URL: https://doaj.org/article/20cee1d07fb040d4ba22ddbe8f6c28ca

Ciltacabtagene Autoleucel for the Treatment of Relapsed/Refractory Multiple Myeloma: Efficacy, Safety, and Place in Therapy

Authors: Goel U, Zanwar S, Cowan AJ, Banerjee R, Khouri J, Dima D

Source: Cancer Management and Research, Vol Volume 17, Pp 357-372 (2025)

Subject Terms: multiple myeloma, ciltacabtagene autoleucel, car t, chimeric antigen receptor t cell therapy, relapsed/refractory multiple myeloma., Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.dovepress.com/ciltacabtagene-autoleucel-for-the-treatment-of-relapsedrefractory-mult-peer-reviewed-fulltext-article-CMAR; https://doaj.org/toc/1179-1322

Access URL: https://doaj.org/article/dacb49bba2e14419887df41973f3bd28

BCMA CAR-T therapy combined with pomalidomide is a safe and effective treatment for relapsed/refractory multiple myeloma

Authors: Yuhan Yan, Yixuan Tu, Qian Cheng, Jian Zhang, Erhua Wang, Zuqun Deng, Yan Yu, Liwen Wang, Rui Liu, Ling Chu, Liqing Kang, Jing Liu, Xin Li

Source: Journal of Translational Medicine, Vol 22, Iss 1, Pp 1-13 (2024)

Subject Terms: Relapsed/Refractory multiple myeloma (R/R MM), BCMA CAR T-cell therapy, Pomalidomide, Combination therapy, Medicine

File Description: electronic resource

Relation: https://doaj.org/toc/1479-5876

Access URL: https://doaj.org/article/a60950bfb0a443be87c9a362b63aaf60

Bortezomib, Mitoxantrone Hydrochloride Liposome, and Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Multi‐Center, Open‐Label Phase I Trial

Authors: Ya‐Lan Zhou, Jin‐Qiao Zhang, Wei Wang, Li Bao, Bai‐Jun Fang, Da Gao, Li‐Ping Su, Wen‐Ming Chen, Guang‐Zhong Yang

Source: Cancer Medicine, Vol 14, Iss 8, Pp n/a-n/a (2025)

Subject Terms: efficacy, mitoxantrone hydrochloride liposome, relapsed/refractory multiple myeloma, safety, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/0ccacd30c0254a27a492c8d55e549294

Real‐world characteristics and outcomes of patients with multiple myeloma receiving second‐line treatment in England

Authors: Sally Moore, Laura Cornic, Christina‐Jane Crossman‐Barnes, Sophie Jose, Zeyad Khalaf, Kwee Yong, Megan Soutar, Philip Woods

Source: eJHaem, Vol 6, Iss 1, Pp n/a-n/a (2025)

Subject Terms: National Cancer Registration and Analysis Service, real‐world evidence, relapsed/refractory multiple myeloma, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/50fc2dbce08b4960bad007f92b9f3c67

Expert Opinion on Multiple Myeloma Treatment in Brazil in the Bispecific Antibody Era

Authors: Hungria, Vania ^{1, #, ⁎}, Pinto Neto, Jorge Vaz ^{2, #}, Garibaldi, Pedro Manoel Marques ³, Jansen, Angela Marie ⁴, Filho, Roberto Jose Pessoa de Magalhães ⁵, Pericole, Fernando Vieira ⁶, Sanku, Gayatri ⁴, Maiolino, Angelo ^{7, 8}

Source: In Clinical Lymphoma, Myeloma and Leukemia April 2025 25(4):e200-e209

Advancing the understanding of venetoclax in t(11;14)-positive multiple myeloma: a comprehensive review of clinical evidence and future prospects

Authors: Abdullah AlZahrani, Nada Alsuhebany, Imran K. Tailor, Abdullah M. Alrajhi

Source: Hematology, Vol 29, Iss 1 (2024)

Subject Terms: Venetoclax, t(11, 14), multiple myeloma, AML, acute myeloid leukemia, BCL2, B-cell lymphoma 2, CAR T-cell, chimeric antigen receptor T-cell, CLL, chronic lymphocytic leukemia, FDA, Food and Drug Administration, IC50, half maximal inhibitory concentration, IL-6: interleukin 6, IMiD, immune-modulators, MM, multiple myeloma, ORR, overall response rate, PFS, progression-free survival, PI, proteasome inhibitor, RRMM, relapsed/refractory multiple myeloma, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/1607-8454

Access URL: https://doaj.org/article/9c59153d5af146aeb7865719eb56c1fe

Treatment pattern among patients with relapsed/refractory multiple myeloma (RRMM) who had received pomalidomide-based regimens in Taiwan

Authors: Chieh-Lin Jerry Teng, Su-Peng Yeh, Tsai-Yun Chen, Yu-Chin Hung, Yun-Chu Lin, Sin Syue Li, Ming-Chung Wang, Shang-Yi Huang

Source: Hematology, Vol 29, Iss 1 (2024)

Subject Terms: Doublet and triplet regimen, pomalidomide, relapsed/refractory multiple myeloma, treatment pattern, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/1607-8454

Access URL: https://doaj.org/article/9593eb70b29941de9fe5b26697691dd5

A systematic review on the epidemiology and treatment options of multiple Myeloma in Asia

Authors: Wee-Joo Chng, Chandramouli Nagarajan, Shang-Yi Huang, Pankaj Malhotra, Yu-Yan Hwang, Vivian Blunk, Manmohan Singh, Lin Wang

Source: Heliyon, Vol 10, Iss 21, Pp e39698- (2024)

Subject Terms: Newly diagnosed multiple myeloma, Relapsed/refractory multiple myeloma, Autologous stem cell transplant, Proteasome inhibitors, B-cell maturation antigen targeted chimeric antigen receptor T-cell therapy, Science (General), Q1-390, Social sciences (General), H1-99

File Description: electronic resource

Relation: http://www.sciencedirect.com/science/article/pii/S2405844024157295; https://doaj.org/toc/2405-8440

Access URL: https://doaj.org/article/f234975d478044bc8c3dd95cf441fbb4

Real-World Treatment Patterns and Clinical Outcomes in Patients With Multiple Myeloma Previously Treated With Lenalidomide and an Anti-CD38 Monoclonal Antibody

Authors: Ramasamy, Karthik ^{1, 2, ⁎}, Vij, Ravi ³, Kuter, David ⁴, Cella, David ⁵, Durie, Brian G.M. ⁶, Abonour, Rafat ⁷, Rifkin, Robert M. ⁸, Ailawadhi, Sikander ⁹, Lee, Hans C. ¹⁰, Cowan, Andrew J. ¹¹, Ho, Carrie ¹¹, Dhanasiri, Sujith ^{12, #}, Fish, Susan ^{13, #}, Yu, Edward ^{13, #}, Dhamane, Amol D. ¹³, Fang, Jiaqi ¹³, Marshall, Thomas S. ¹³, Samuel, Amir ¹³, Liu, Liang ¹³, Katz, Jessica ¹³, Gu, Tao ¹³, Jagannath, Sundar ¹⁴

Source: In Clinical Lymphoma, Myeloma and Leukemia May 2025 25(5):337-348

CAR-T and Bispecific Antibodies: The New Standard for Relapsed and Refractory Multiple Myeloma, or Reserved for Late-Line Salvage Therapy?

Authors: Paula Rodriguez-Otero, Thomas Martin

Source: Hemato, Vol 5, Iss 2, Pp 171-179 (2024)

Subject Terms: immunotherapy, relapsed/refractory multiple myeloma, CAR T, bispecific antibodies, T-cell engager, Medicine

File Description: electronic resource

Relation: https://www.mdpi.com/2673-6357/5/2/14; https://doaj.org/toc/2673-6357

Access URL: https://doaj.org/article/f1fcc3e73eef4e409a17047281c1673a

Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical Trials

Authors: Costa, Bruno Almeida ^{1, 2}, Costa, Thomaz Alexandre ³, Chagas, Gabriel Cavalcante Lima ⁴, Mouhieddine, Tarek H. ⁵, Richter, Joshua ⁵, Usmani, Saad Z. ^{1, 6, 7}, Mailankody, Sham ^{1, 7}, Rajeeve, Sridevi ^{1, *, #}, Hashmi, Hamza ^{1, *, ##}

Source: In Clinical Lymphoma, Myeloma and Leukemia January 2025 25(1):32-44

Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma

Authors: Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar

Source: BMC Cancer, Vol 24, Iss 1, Pp 1-7 (2024)

Subject Terms: relapsed/refractory multiple myeloma, Surrogate endpoint, Progression-free survival, Overall survival, Instrumental variable, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/1471-2407

Access URL: https://doaj.org/article/0585a86fa1414c2e9c7c39d6be67cf00

Identifying clinical response to daratumumab therapy in relapsed/refractory multiple myeloma using a patient‐derived in vitro model

Authors: Niels vanNieuwenhuijzen, Marta Cuenca, Leonie Abbink, Margot Jak, Victor Peperzak, Monique C. Minnema

Source: eJHaem, Vol 5, Iss 1, Pp 141-146 (2024)

Subject Terms: daratumumab, multiple myeloma, patient‐derived plasma cells, relapsed/refractory multiple myeloma, response to therapy, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://doaj.org/toc/2688-6146

Access URL: https://doaj.org/article/95d9a0b5891146baa3b34ed4e6f85dfc

Tumor Lysis Syndrome with Venetoclax/Carfilzomib/Dexamethasone for Relapsed/Refractory Multiple Myeloma: A Case Report

Authors: Reilly Fankhauser, Alan Lu, Adetola Kassim, Eden Biltibo

Source: Reports, Vol 7, Iss 4, p 108 (2024)

Subject Terms: relapsed refractory multiple myeloma (RRMM), tumor lysis syndrome (TLS), venetoclax, BCL-2, t(11, 14), Medicine (General), R5-920, Medical physics. Medical radiology. Nuclear medicine, R895-920

File Description: electronic resource

Relation: https://www.mdpi.com/2571-841X/7/4/108; https://doaj.org/toc/2571-841X

Access URL: https://doaj.org/article/a10b9637da014eb4aec8decf2fa91a08

Experience of Daratumumab in Relapsed/Refractory Multiple Myeloma: A Multicenter Study from Türkiye

Authors: Atakan Tekinalp, Ayfer Gedük, Aydan Akdeniz, Esra Terzi Demirsoy, Vildan Gürsoy, Müzeyyen Aslaner Ak, Metin Bağcı, Sema Seçilmiş, Fatma Keklik Karadağ, Ayşe Oruç Uysal, Ali Doğan, Sinan Demircioğlu, Haşim Atakan Erol, Ceyda Aslan, Fahir Özkalemkaş, Şehmus Ertop, Mehmet Dağlı, Mehmet Sinan Dal, Güray Saydam, Mustafa Merter, Cihan Ural, Özcan Çeneli

Source: Turkish Journal of Hematology, Vol 40, Iss 4, Pp 242-250 (2023)

Subject Terms: daratumumab, relapsed/refractory multiple myeloma, real-world data, Diseases of the blood and blood-forming organs, RC633-647.5

File Description: electronic resource

Relation: https://jag.journalagent.com/z4/download_fulltext.asp?pdir=tjh&un=TJH-20586; https://doaj.org/toc/1308-5263

Access URL: https://doaj.org/article/4debcdb81b4a4484a3947f563fe04669

Allogeneic stem cell transplantation in multiple myeloma: is there still a place?

Authors: Carmine Liberatore, Francesca Fioritoni, Mauro Di Ianni

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: allogeneic transplantation, multiple myeloma, immunotherapy, relapsed refractory multiple myeloma, alternative donor, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1402106/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f3529d442e224ade89fa39162684ba30

Efficacy and safety of once weekly selinexor 40 mg versus 60 mg with pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma

Authors: Darrell White, Gary J. Schiller, Sumit Madan, Suzanne Lentzsch, Evgeni Chubar, Noa Lavi, Dane R. Van Domelen, Ohad S. Bentur, Muhamed Baljevic

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: selinexor, once weekly dose, optimal triplet combination, relapsed/refractory multiple myeloma, pomalidomide, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1352281/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/faf3645ed4d642638bc528022e510fa6

A real‐world retrospective–prospective analysis of efficacy and safety of combined ixazomib, lenalidomide, and dexamethasone in relapsed/refractory multiple myeloma: The northern Italy experience

Authors: Anna Furlan, Michele Cea, Laura Pavan, Monica Galli, Cristina Clissa, Silvia Mangiacavalli, Anna Maria Cafro, Stefania Girlanda, Francesca Patriarca, Claudia Minotto, Giovanni Bertoldero, Gregorio Barilà, Anna Pascarella, Albana Lico, Rossella Paolini, Nicholas Rabassi, Norbert Pescosta, Marika Porrazzo, Giovanni De Sabbata, Alessandra Pompa, Giulia Bega, Stefania Cavallin, Francesca Guidotti, Magda Marcatti, Maurizio Rupolo, Angelo Belotti, Filippo Gherlinzoni, Renato Zambello

Source: Cancer Medicine, Vol 13, Iss 7, Pp n/a-n/a (2024)

Subject Terms: efficacy, ixazomib–lenalidomide–dexamethasone, lenalidomide‐exposed, lenalidomide‐refractory, real‐life, relapsed/refractory multiple myeloma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://doaj.org/toc/2045-7634

Access URL: https://doaj.org/article/0408a307c22a4cd197324662a7fb060f

Autologous hematopoietic stem cell transplantation for multiple myeloma in the age of CAR T cell therapy

Authors: Charlotte F. M. Hughes, Gunjan L. Shah, Barry A. Paul

Source: Frontiers in Oncology, Vol 14 (2024)

Subject Terms: autologous transplant, CAR T cell therapy, multiple myeloma, newly diagnosed multiple myeloma, relapsed refractory multiple myeloma, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, RC254-282

File Description: electronic resource

Relation: https://www.frontiersin.org/articles/10.3389/fonc.2024.1373548/full; https://doaj.org/toc/2234-943X

Access URL: https://doaj.org/article/f41d1f832b2d465bb373f43bf2b7703c